Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Date

07 Oct 2016

Session

CNS tumours

Presenters

Enrico Franceschi

Citation

Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367

Authors

E. Franceschi1, D. De Biase2, A. Paccapelo1, M. Reni3, A. Mura1, G. Tallini2, C. Bortolotti4, L. Volpin5, G. Marucci6, L. Cirillo7, A. Pession2, C. Ghimenton8, R. Poggi1, S. Bartolini1, L. Albini Riccioli7, A. Tosoni1, C. Degli Esposti9, D. Danieli10, G. Genestreti1, A.A. Brandes1

Author affiliations

  • 1 Medical Oncology, Bellaria - Maggiore Hospitals, Azienda USL - IRCCS Institute of Neurological Sciences, 40139 - Bologna/IT
  • 2 Department Of Biomedical And Neuromotor Sciences (dibinem), Section Of Pathology, M. Malpighi, Bellaria Hospital, University of Bologna, 40139 - Bologna/IT
  • 3 Medical Oncology, IRCCS San Raffaele, 20132 - Milano/IT
  • 4 Neurosurgery, Irccs, Istituto Delle Scienze Neurologiche Di Bologna, Ospedale Bellaria, 40139 - Bologna/IT
  • 5 Department Of Neuroscience And Neurosurgery, Ospedale San Bortolo, 36100 - Vicenza/IT
  • 6 Section Of Pathology, M. Malpighi, Bellaria Hospital, 40139 - Bologna/IT
  • 7 Irccs Institute Of Neurological Sciences, Unit Of Neuroradiology, Ospedale Bellaria, Bologna/IT
  • 8 Pathology Department, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Trento", 37126 - Verona/IT
  • 9 Radiotherapy, Bellaria - Maggiore Hospitals, Azienda USL - IRCCS Institute of Neurological Sciences, 40139 - Bologna/IT
  • 10 Department Of Pathology, Ospedale San Bortolo, 36100 - Vicenza/IT
More

Resources

Abstract 2123

Background

Molecular characterization of low grade gliomas (LGG) has improved in recent years and is essential for diagnosis and treatment of these diseases. Moreover, clinical factors, such as age and the extent of surgery retain a prognostic role in LGG that were assessed for IDH1/2, 1p/19q codeletion, and MGMT methylation status.

Methods

we retrospectively evaluated all adult LGG patients (pts) from our data warehouse who received surgery and had sufficient tissue to assess biomarkers characterization. IDH1/2 assessment was performed on formalin-fixed paraffin-embedded samples by PCR, MGMT by methylation specific PCR, 1p/19 codeletion by FISH.

Results

198 consecutive LGG were included. The median age was 38 (range:18–72). Median follow up was 74.0 months, 109 pts (55.1%) were

Conclusions

Molecular characteristic of LGG define the prognosis of these tumors. Moreover, clinical risk assessment retains a role even in the era of molecular characterization.

Clinical trial identification

Legal entity responsible for the study

Azienda USL / IRCCS Institute of Neurological Sciences of Bologna

Funding

Azienda USL / IRCCS Institute of Neurological Sciences of Bologna

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings